Guillain‑Barré syndrome and severe infection following chemotherapy for peripheral T‑cell lymphoma: A case report

Ma,Yang‑Yang; Zhang,Lei; Zhang,Da‑Liang; Liu,Wen‑Shuo

doi:10.3892/ol.2014.2541

Guillain‑Barré syndrome and severe infection following chemotherapy for peripheral T‑cell lymphoma: A case report

Authors:
- Yang‑Yang Ma
- Lei Zhang
- Da‑Liang Zhang
- Wen‑Shuo Liu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450002, P.R. China
Published online on: September 16, 2014 https://doi.org/10.3892/ol.2014.2541
Pages: 2695-2698

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Guillain‑Barré syndrome (GBS) is a rare complication of malignant lymphoma. The current study describes a case of GBS in a patient with peripheral T‑cell lymphoma not otherwise specified (PTCL‑NOS). A 47‑year‑old male was admitted to the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) with systemic multiple subcutaneous nodules and was diagnosed with stage IV high‑grade PTCL‑NOS (according to the Revised European American Lymphoma Classification). During chemotherapy, severe infection and progressive flaccid quadriparesis appeared, which eventually developed to respiratory muscles paralysis. The clinical course and neurological examination were consistent with GBS. Following mechanical ventilation and intravenous immunoglobulin administration, the neurological symptoms were in remission after one month. Three months later, the patient achieved complete remission without any treatment during this period. We hypothesized that immune reconstruction may have a significant role in this phenomenon.

View Figures

View References

1	Agostinelli C, Piccaluga PP, Went P, et al: Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol. 61:1160–1167. 2008.
2	Piccaluga PP, Agostinelli C, Gazzola A, et al: Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep. 5:222–228. 2010.
3	Foss FM, Zinzani PL, Vose JM, et al: Peripheral T-cell lymphoma. Blood. 117:6756–6767. 2011.
4	Savage KJ: Therapies for peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2011:515–524. 2011.
5	Zinzani PL, Venturini F, Stefoni V, et al: Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 21:860–863. 2010.
6	Pulini S, Rupoli S, Goteri G, et al: Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica. 92:686–689. 2007.
7	Winer JB: Guillain-Barré Syndrome. Mol Pathol. 54:381–385. 2001.
8	Hughes RA and Cornblath DR: Guillain-Barré syndrome. Lancet. 366:1653–1666. 2005.
9	Yuki N and Hartung HP: Guillain-Barré syndrome. New Engl J Med. 366:2294–2304. 2012.
10	Hughes RA, Swan AV, Raphaël JC, et al: Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 130:2245–2257. 2007.
11	Rupniewska ZM: Role of the Ann Arbor classification in the staging of non-Hodgkin’s lymphomas. Pol Arch Med Wewn. 61:317–321. 1979.
12	Ciesla N, Dinglas V, Fan E, et al: Manual muscle testing: a method of measuring extremity muscle strength applied to critically ill patients. J Vis Exp. 50:26322011.
13	Lisak RP, Mitchell M, Zweiman B, et al: Guillain-Barré syndrome and Hodgkin’s disease: Three cases with immunological studies. Ann Neurol. 1:72–78. 1977.
14	Julien J, Vital C, Aupy G, et al: Guillain-Barré syndrome and Hodgkin’s disease: Ultrastructural study of a peripheral nerve. J Neurol Sci. 45:23–27. 1980.
15	Fujisaki G, Kami M, Murashige N, et al: Guillain-Barré syndrome associated with rapid immune reconstitution following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 37:617–619. 2006.
16	Hernández-Boluda JC, Lis MJ, Goterris R, et al: Guillain-Barré syndrome associated with cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 7:93–96. 2005.
17	Rodriguez V, Kuehnle I, Heslop HE, et al: Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 29:5152002.
18	Sasannejad P, Azarpazhooh MR, Rahimi H, et al: Guillain-Barré-like Syndrome, as a Rare Presentation of Adult T-cell Leukemia-Lymphoma (ATLL): A Case Report. Iran Red Crescent Med J. 14:4972012.
19	Re D, Schwenk A, Hegener P, et al: Guillain-Barré syndrome in a patient with non-Hodgkin’s lymphoma. Ann Oncol. 11:217–220. 2000.
20	Polo-Romero FJ, Sánchez-Beteta P, Perona-Buendía P and Pérez-García AM: Guillain-Barré syndrome as first presentation of non-Hodgkin lymphoma. Neurologia. 27:511–513. 2012.
21	Machida H, Shinohara T, Hatakeyama N, et al: CD5-positive diffuse large B cell lymphoma infiltrating the central nervous system presenting Guillain-Barré-like syndrome after chemotherapy. J Clin Exp Hematopathol. 52:199–204. 2012.
22	Kirkwood JM, Butterfield LH, Tarhini AA, et al: Immunotherapy of cancer in 2012. CA Cancer J Clin. 62:309–335. 2012.
23	Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
24	Stevens PL and Reddy NM: Immune surveillance and lymphoid malignancy in immunocompromised host. Am J Blood Res. 3:912013.
25	de la Cruz-Merino L, Lejeune M, Nogales Fernández E, et al: Role of immune escape mechanisms in Hodgkin’s lymphoma development and progression: a whole new world with therapeutic implications. Clin Dev Immunol. 2012:7563532012.
26	Steiner I, Rosenberg G and Wirguin I: Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome? Clin Exp Immunol. 162:32–40. 2010.
27	Tiwari M: From tumor immunology to cancer immunotherapy: miles to go. J Cancer Res Ther. 6:427–31. 2010.
28	Couzin-Frankel J: Immune therapy steps up the attack. Science. 330:440–443. 2010.